Previous studies have shown that DMXL2, NME8, and FBN1 primarily exert oncogenic roles through mutations and splice variants (16–18); moreover, the role of SCD in CML has also been reported previously (19). The gene discussed is DMXL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.